Clinical Trials · NCT07456774
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
- Phase
- N/A
- Recruitment status
- Enrolling By Invitation
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 100,000
- Start date
- Feb 2026
- Locations
- 1 site, China
- Primary endpoint
- Time to 3P major adverse cardiovascular events